Table 1.
Demographic and clinical data of 3 HTLV-1 cohorts.
| Cohorts | HC | AC | HAM/TSP | Cell type |
|---|---|---|---|---|
| Cohort 1 (Sao Paulo, BR) | CD4+ T cells | |||
| Number of samples | 5 | 6 | 7 | |
| Age (median, IQR) | 54(38–61) | 62(54–66) | 51(45–62) | |
| Gender | 1M/4F | 1M/5F | 2M/5F | |
| PVL (median, ± SD) | N/A | 7.6 ± 151.5 | 181.0 ± 134.5 | |
| Tax mRNA (median, ± SD) | N/A | 0.02 ± 0.02 | 0.68 ± 0.77 | |
| HBZ mRNA (median, ± SD) | N/A | 10−5 ± 5.4 10−4 | 2.7 10−4 ± 8.1 10−4 | |
| Cohort 2 (Bahia, BR) | PBMC | |||
| Number of samples | 11 | 5 | 10 | |
| Age (median, IQR) | 52 ± 6.2 | |||
| Gender | 4M/7F | 2M/3F | 4M/6F | |
| Cohort 3 (published; London, UK) | Whole blood | |||
| Number of samples | 8 | 17 | 10 | |
| Age (median, IQR) | 49(46–71) | 47(38–62) | 54(49–62) | 63(44–74) |
| Gender | 4M/4F | 0M/17F | 4M/6F | |
| PVL (median, IQR) | N/A | 0.6(0.4–0.9) | 3.9 (3.4–6.7) | 10.1(6.7–17.8) |
| Total number of individuals | 24 | 23 | 27 |